Robert W. Baird analyst Drew Babin reiterated a Hold rating on HCP Inc (NYSE: HCP) yesterday and set a price target of $26. The company’s shares closed yesterday at $26.09.
According to TipRanks.com, Babin is a 4-star analyst with an average return of 9.2% and a 77.8% success rate. Babin covers the Financial sector, focusing on stocks such as Bluerock Residential Growth, Physicians Realty Trust, and Education Realty Trust.
HCP Inc has an analyst consensus of Moderate Buy, with a price target consensus of $27.17, a 4.1% upside from current levels. In a report issued on August 7, Cantor Fitzgerald also initiated coverage with a Hold rating on the stock with a $28 price target.
.
See today’s analyst top recommended stocks >>
Based on HCP Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $89.48 million. In comparison, last year the company had a net profit of $19.28 million.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HCP in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HCP, Inc. is a real estate investment trust which invests primarily in real estate serving the healthcare industry in the United States. It acquires, develops, leases, sells, and manages healthcare real estate and provides mortgage and other financing to healthcare providers.
